Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More

Leinco Technologies Inc Anti-Mouse CD86 (B7-2, B70, Ly-58) In Vivo PLATINUM; Clone GL-1; Isotype: Rat IgG2a κ
SDP

Supplier:  Leinco Technologies Inc C6158100 MG

Encompass_Preferred

Specificity: Clone GL-1 recognizes an epitope on mouse CD86. Antigen Distribution: This antigen is expressed on activated B and T cells, macrophages, dendritic cells, and astrocytes. Background: CD86 is an 80 kDa glycoprotein and a member of the Ig superfamily. CD86 is a ligand for CD28 and CD152 (CTLA-4). CD86 is related to the CD80 molecule and functions as a counter receptor for CD28 and CTLA-4. The GL1 clone has been shown to provide critical signals for T-Cell-dependent responses In vivo and In vitro. Applications: (WB, B, IF) Clone GL1 has been shown to block CD86 In vivo and inhibit the priming of cytotoxic T cells. Leinco’s In vivo GOLDTM and In vivo PLATINUMTM functional antibodies are manufactured in an animal free facility using only In vitro cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.

Catalog No. 50-190-6177


May include imposed supplier surcharges.
Only null left
Add to Cart

Product Content Correction

The Fisher Scientific Encompass Program offers items which are not part of our distribution portfolio. These products typically do not have pictures or detailed descriptions. However, we are committed to improving your shopping experience. Please use the form below to provide feedback related to the content on this product.

Product Title

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.

Your feedback has been submitted: Thank you for helping us improve our website.